350 rub
Journal Technologies of Living Systems №7 for 2011 г.
Article in number:
Abnormalities of Haemostasis in Cancer Patients with Thrombosis and Thromboembolic of Pulmonary Artery, which Occurred During Subacute Disseminated Intravascular Coagulation
Keywords: oncology haemostasis thrombosis LMWH
Authors:
O.V. Somonova, A.V. Madzhuga, A.L. Elizarova
Abstract:
The main chains of haemostatic system (procoagulant, anticoagulant, fibrinolytic, platelet function) were studied in 30 cancer patients with acute thrombosis and thromboembolic of pulmonary artery (VTE). Automatic analyzer STA-R EVOLUTION was used. The patients received low-molecular-weight heparins (LMWH): 200 U/kg once daily or 100 U/kg twice daily. Period VTE was characterized by subacute disseminated intravascular coagulation with consumption of fibrinogen, protrombin, antithrombin III, plasminogen, protein C, significant increase D-dimer, von Willebrand factor. In spite of decrease of coagulation factors and platelet count, the use of LMWHs in therapeutic doses decreased the activity of intravascular coagulation, restore coagulation factors. The use of LMWHs is an effective and adequate method of antithrombotic treatment in oncological patients. Venous thrombosis were no. No cases of pulmonary embolism developed. The antifactor-Xa activity of LMWH was in the therapeutic range for treatment (0,5-1,0 IU/ml). There were no hemorrhagic complications
Pages: 34-39
References
  1. Bromberg M.E., Cappello M. Cancer and blood coagulation: molecular aspects // Cancer. 1999. V. 3. P. 132 - 138.
  2. Schmitt M., Kuhn W., Hardee N., Grief H. Thrombophilic state in breast cancer // Seminars in double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high risk abdominal surgery: the PEGASUS Study (abstract) // Blood. 2003. V.102. P. 15a.
  3. Levine M.N., Lee A.Y., Kakkar A.K Thrombosis and cancer.// American Society of Clinical Oncology, 41 Annual Meeting. 2005. May 13 - 17. P. 748 - 577.
  4. Zwicker J.I. Predictive value of factor bearing microparticles in cancer associated thrombosis // Thromb. Research. 2010. V. 125. Suppl. 2.  P. S89-S91.
  5. Cicco M. The prothrombotic state in cancer: pathogenic mechanisms // Crit Rev Oncol Hematol. 2004. V. 50 (3). P. 187 - 196.
  6. Eilertsen K.E., Osterud B. Tissue factor: pathophisiolody and cellular biology // Bood Coagul. Fibrinolysis. 2004. V. 15 (7). P. 521 - 538.
  7. Turkstra F., Koopman M.M., Buller H.R. The treatment of deep vein thrombosis and pulmonary embolism // Thromb. Haemost. 1997. V. 78. P. 489 - 496.
  8. Rickles F., Falanga A. A Molecular basis for the relationship between thrombosis and cancer // Thromb. Res. 2001. V. 102. P. 215 - 224.
  9. Sallah S., Wan J.Y., Nquyen N.P. et al. Disseminated intravascular coagulation in  solid tumors: clinical and pathologic study// Thromb. Haemost. 2001. V. 86 (3). P. 828 - 833.
  10. Ornstein D.L., Zacharski L.R. The use of heparin fir treating human malignancies // Haemostasis. 1999. V. 29. Supp. l. P. 48 - 60.
  11. Becker R.C., Fintel D.J., Green D. Antithrombotic therapy. 2th ed. U.S.A. 2002. 352 p.
  12. Buller H.R., Sohne M., Middeldorp S. Treatment of venous thromboembolism // JHT. 2005. V. 3. №8. P. 1554 - 1560.
  13. Hyers T.M., Agnelii G., Hull R.D. et al. Antithrombotic therapy for venous thromboembolic disease // Chest. 2001. V. 119. Suppl. 1. P. 176.